Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)
Rapid reduction and sustained normalization of heparan sulfate in CSF demonstrated robust and durable CNS…